Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO John E. Kao Sells 90,000 Shares

Alignment Healthcare, Inc. (NASDAQ:ALHC - Get Free Report) CEO John E. Kao sold 90,000 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $14.23, for a total value of $1,280,700.00. Following the sale, the chief executive officer now directly owns 2,183,100 shares of the company's stock, valued at approximately $31,065,513. The trade was a 3.96 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Alignment Healthcare Stock Down 1.4 %

ALHC traded down $0.19 during trading hours on Friday, reaching $13.68. The company's stock had a trading volume of 1,222,559 shares, compared to its average volume of 2,003,122. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 1.82. The business's 50-day moving average is $12.95 and its 200-day moving average is $11.61. Alignment Healthcare, Inc. has a fifty-two week low of $4.46 and a fifty-two week high of $15.82.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ALHC. UBS Group lifted their target price on Alignment Healthcare from $9.00 to $12.00 and gave the company a "neutral" rating in a research report on Wednesday, October 30th. Stifel Nicolaus upped their price target on Alignment Healthcare from $14.00 to $16.00 and gave the stock a "buy" rating in a report on Tuesday, January 14th. Barclays upped their price target on Alignment Healthcare from $7.00 to $8.00 and gave the company an "underweight" rating in a research report on Wednesday, October 30th. Finally, Stephens reaffirmed an "overweight" rating and issued a $17.00 price target on shares of Alignment Healthcare in a report on Thursday, January 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $11.88.

Institutional Investors Weigh In On Alignment Healthcare

Hedge funds have recently added to or reduced their stakes in the company. R Squared Ltd acquired a new position in shares of Alignment Healthcare in the 4th quarter valued at $55,000. nVerses Capital LLC acquired a new stake in shares of Alignment Healthcare in the 3rd quarter worth approximately $95,000. RiverPark Advisors LLC acquired a new stake in Alignment Healthcare during the fourth quarter valued at approximately $106,000. Tower Research Capital LLC TRC raised its holdings in shares of Alignment Healthcare by 146.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,571 shares of the company's stock valued at $119,000 after acquiring an additional 6,286 shares during the period. Finally, Ballentine Partners LLC acquired a new position in Alignment Healthcare in the 4th quarter valued at approximately $121,000. Institutional investors and hedge funds own 86.19% of the company's stock.

About Alignment Healthcare

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.